The FDA refused to accept uniQure's filing for AMT-130 last November, and earlier this year the Dutch biotech said it had ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

This article was developed and funded by Gilead Sciences Ltd. For decades, the UK life sciences sector has been the jewel in ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Andrew Cavey, CEO of ITM, about current and future ...

The late-stage MonumenTAL-3 trial of Talvey (talquetamab), given in combination with J&J and Genmab's anti-CD38 antibody ...

A UK study has used dispensing data to understand how medicine use in England changed during and after the COVID-19 pandemic, ...

Poolbeg Pharma is preparing to start a clinical trial of a drug that aims to block a life-threatening side effect of cancer ...

A new study will attempt to improve screening for one of the fastest-growing drug-resistant bacterial threats facing ...

Eisai has been given a grant from the UK government that will be used to expand a facility in Hatfield, Hertfordshire, which ...

Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

The FDA has started a review of Gilead Sciences' once-weekly oral medicine for HIV pre-exposure prophylaxis (PrEP), and is due to deliver its verdict by 2nd February next year. If approved, the oral ...

Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their ...